series-c-plus
Stage
2
Investors
About
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company utilizes its RAP technology platform to target specific neuronal receptor complexes, aiming to transform the standard of care for neurological diseases.
Explore Rapport Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.